Federal Contractor Profile
Siga Technologies, INC.
Federal contracting record: $724M obligated across 6 awards from 2 agencies, FY 2016–2026.
$724M
Total Obligated
6
Award Records
2
Agencies Served
3
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
VJRNRTSL22K4
CAGE Code
1V4X4
Address
27 E 62ND ST, NEW YORK, NY, 100658014
First Federal Award
Dec 10, 2015
Most Recent Award
Aug 24, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$696M
96.1% of total obligations
- Department of Defense$28M
3.9% of total obligations
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Aug 7, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $2.1M → |
| Jun 3, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $13M → |
| Apr 7, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $14M → |
| Mar 24, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $26M → |
| Aug 2, 2024 | Department of DefenseW6QK ACC-APG | 325412 | PROCUREMENT OF 23,030 TPOXX ORAL COURSES AND 50 TPOXX IV COURSES. TO MAINTAIN NATIONAL STOCKPILE. | $9.0M → |
| Jul 16, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $113M → |
| Feb 15, 2024 | Department of DefenseW6QK ACC-APG | 325412 | PROCURE UP TO 23000 TPOXX COURSES FOR SMALL POX TREATMENT. | $1.1M → |
| Jul 27, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $138M → |
| Mar 30, 2023 | Department of DefenseW6QK ACC-APG | 325412 | PROCURE UP TO 23000 TPOXX COURSES FOR SMALL POX TREATMENT. | $5.5M → |
| Sep 29, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | DRUGS AND BIOLOGICALS | $2.6M → |
| Sep 28, 2022 | Department of DefenseW6QK ACC-APG | 325412 | PROCURE UP TO 23000 TPOXX COURSES FOR SMALL POX TREATMENT. | $5.2M → |
| Aug 25, 2022 | Department of DefenseW6QK ACC-APG | 325412 | PROCURE COURSES OF FDA APPROVED TPOXX DRUG/THERAPEUTIC | $3.8M → |
| Aug 4, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $29M → |
| May 12, 2022 | Department of DefenseW6QK ACC-APG | 325412 | PROCURE COURSES OF FDA APPROVED TPOXX DRUG/THERAPEUTIC | $3.6M → |
| Feb 3, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | CONTRACT AWARD HHSN272200800041C UNDER BAA NIH-NIAID-DMID-08-20 | $220K → |
| Sep 7, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $113M → |
| Apr 26, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $15K → |
| Jul 2, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | CONTRACT AWARD HHSN272200800041C UNDER BAA NIH-NIAID-DMID-08-20 | $2K → |
| Apr 23, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $101M → |
| Sep 5, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $2.4M → |
| May 22, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | CONTRACT AWARD HHSN272200800041C UNDER BAA NIH-NIAID-DMID-08-20 | $2.1M → |
| May 20, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $11M → |
| Feb 21, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $12M → |
| Sep 10, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | $52M → |
| Jul 30, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | DRUGS AND BIOLOGICALS | $50M → |
Want to win work like Siga Technologies, INC.?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.